STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts - WuXi Biology

Access Resources

Thank you for your interest in our resources. Please fill out the information here to have full access to our library of useful information, including what you are looking for currently.

Name(Required)

Work Email(Required)

Company(Required)

Your Region(Required)

Your Country

U.S. State

European Country

This field is hidden when viewing the form

Your Country

This field is hidden when viewing the form

U.S. State

This field is hidden when viewing the form

Territory

← Return to Resources

Related Content

AACR 2026 Posters: Sneak Peek

AACR 2026 Posters | Sneak Peek The Annual Meeting of the American Association for Cancer Research (AACR) will be held...

VIEW RESOURCE

Poster Presentations at AACR 2026

At AACR 2026, scientists from our WuXi Biology platform will present a collection of the company’s latest oncology research findings...

VIEW RESOURCE

← View all Oncology Resources

×

Access Resources

Related Content

AACR 2026 Posters: Sneak Peek

Poster Presentations at AACR 2026

Contact An Expert Today!